"Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) today announced that its supplemental New Drug Application (sNDA) for TREXIMET (sumatriptan / naproxen sodium) has been accepted by the U.S. Food and Drug Administration (FDA). Approval is expected in 2Q 2015, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date."
Multiple streams of revenue. Recorded high income last year. Higher income expected this year.
HEB is doing well